T-817 is a thiophenylalkyl derivative patented by Toyama Chemical Co., Ltd. as a neuroprotectant for the treatment of Alzheimer's disease. T-817MA protects neurons against amyloid-b peptide- and hydrogen peroxide-induced neurotoxicity and promoted neurite outgrowth in hippocampal slice cultures and neuronal reaggregation culture. T-817MA protected against nitric oxide-induced neurotoxicity in cultured primary neurons. In a preclinical model of Alzheimer's disease, T-817 increases decreased dopamine levels and tyrosine hydroxylase immunostaining in mice's substantia nigra (SNc) and striatum. Systemic administration of T-817 rescues tau-induced synaptic abnormalities.